Akorn To File Amended Unaudited Financial Statements For The Quarter Ended March 31, 2012
Akorn, Inc. (NASDAQ: AKRX), a niche generic pharmaceutical company,
today announced that it will restate the previously issued unaudited
financial statements contained in its Quarterly Report on Form 10-Q for
Shares of Valeant Pharmaceuticals jumped following last night's report by The Wall Street Journal saying that the company rejected a joint takeover approach from Takeda Pharmaceuticals and TGP Capital.